Home>Topics>Companies>IMS Health

IMS Health RX

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Belviq Sales Crack Critical Level


      Fri, 29 Aug 2014

      the numbers last week. For the first time, sales of Belviq eclipsed the 11,000 level according to industry tracker IMS Health (NYSE: IMS ). The reason that the 11,000 level is critical is that it has represented a sales ceiling for another

    2. Mylan files ANDA for generic Copaxone


      Thu, 28 Aug 2014

      expects to be eligible for 180 days' market exclusivity (although this is based on the "first to file"). According to IMS Health , Copaxone generated ~$412M in U.S. sales over the 12-month period ending June 30, 2014. Post your comment!

    3. Belviq Sales Rise 2%


      Mon, 25 Aug 2014

      continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker IMS Health . The fact that Belviq has been able to avoid a dip in sales is a testament to the fact that it is new as well as the

    4. Mylan launches generic version of Klor-Con


      Fri, 22 Aug 2014

      with or without metabolic alkalosis , digitalis intoxication and hypokalemic familial periodic paralysis. According to IMS Health , the U.S. market is ~$135M. Post your comment!

    5. Vitaros launches in Germany


      Mon, 18 Aug 2014

      dysfunction (ED), Vitaros ( alprostadil plus excipient), in Germany by Sandoz affiliate Hexal AG. According to IMS Health , the German ED market is ~$150M. Under the terms of its license agreement with Sandoz, Apricus is eligible to receive

    6. Belviq Sales Flatten Out But Edge Above Qsymia


      Fri, 15 Aug 2014

      investors this week is that scripts were slightly down. The good news this week is that for the first time (using IMS Health numbers) Belviq sales were above the levels reported for Vivus's (NASDAQ: VVUS ) Qsymia. Belviq edged out Qsymia

    7. Drug Patent Expirations This Week: Pfizer's Nicotine Spray, Transdermal Hormones


      Wed, 13 Aug 2014

      prescription nicotine inhaler/insuffation device for smoking cessation, also saw a patent expire this week. A report citing IMS Health data indicates that as of 2011, Nicotrol sales were in the $6 million range, well behind then-market leader Chantix

    8. Belviq Scripts Flat For Arena


      Mon, 4 Aug 2014

      will be needed to model good estimates going forward. After the last quarterly call, I lower my upward adjustment to IMS health script numbers from 10% to 5%. Immediately some very passionate Arena investors saw this a a move to downplay sales

    9. More on IMS Q2 results


      Thu, 24 Jul 2014

      IMS Health Holdings (NYSE: IMS ) Q2 results : Revenue: $662M (+6.1%), Information: $386M (+1.8%), Technology Services

    10. IMS Health beats by $0.02, beats on revenue


      Thu, 24 Jul 2014

      IMS Health (NYSE: IMS ): Q2 EPS of $0.39 beats by $0.02 . Revenue of $662M (+6.1% Y/Y) beats by $7.08M . Press Release Post your comment!

    « Prev12345Next »
    Content Partners